These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 2788755)

  • 41. Conjugation of anti-My9 antibody to stealth monensin liposomes and the effect of conjugated liposomes on the cytotoxicity of immunotoxin.
    Sudhan Shaik M; Kanikkannan N; Singh M
    J Control Release; 2001 Oct; 76(3):285-95. PubMed ID: 11578743
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Specific targeting of human hepatocellular carcinoma cells by immunoliposomes in vitro.
    Moradpour D; Compagnon B; Wilson BE; Nicolau C; Wands JR
    Hepatology; 1995 Nov; 22(5):1527-37. PubMed ID: 7590672
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin.
    Pastorino F; Mumbengegwi DR; Ribatti D; Ponzoni M; Allen TM
    J Control Release; 2008 Feb; 126(1):85-94. PubMed ID: 18166243
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting chemotherapy using antibody-combined liposome against human pancreatic cancer cell-line.
    Akaishi S; Kobari M; Takeda K; Matsuno S
    Tohoku J Exp Med; 1995 Jan; 175(1):29-42. PubMed ID: 7610458
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of liposomes containing sodium butyrate conjugated with anti-CD19 monoclonal antibody on in vitro and in vivo growth of malignant lymphoma.
    Watanabe M; Pesando JM; Hakomori S
    Cancer Res; 1990 Jun; 50(11):3245-8. PubMed ID: 1692257
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
    Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
    Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation in vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker.
    Greenfield RS; Kaneko T; Daues A; Edson MA; Fitzgerald KA; Olech LJ; Grattan JA; Spitalny GL; Braslawsky GR
    Cancer Res; 1990 Oct; 50(20):6600-7. PubMed ID: 2208122
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antitumor effect of actinomycin D entrapped in liposomes bearing subunits of tumor-specific monoclonal immunoglobulin M antibody.
    Hashimoto Y; Sugawara M; Masuko T; Hojo H
    Cancer Res; 1983 Nov; 43(11):5328-34. PubMed ID: 6616468
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Doxorubicin-conjugated anti-midkine monoclonal antibody as a potential anti-tumor drug.
    Inoh K; Muramatsu H; Torii S; Ikematsu S; Oda M; Kumai H; Sakuma S; Inui T; Kimura T; Muramatsu T
    Jpn J Clin Oncol; 2006 Apr; 36(4):207-11. PubMed ID: 16611663
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The use of anthracycline-antibody complexes for specific antitumor activity.
    Pietersz GA; Smyth MJ; Farquhar I; McKenzie C
    Targeted Diagn Ther; 1988; 1():25-53. PubMed ID: 2979059
    [No Abstract]   [Full Text] [Related]  

  • 51. In vitro targeting and cytotoxicity of adriamycin in liposomes bearing monoclonal antibody against rat or human gp125 cell proliferation-associated antigen.
    Tanaka T; Suzuki S; Masuko T; Hashimoto Y
    Jpn J Cancer Res; 1989 Apr; 80(4):380-6. PubMed ID: 2501255
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-laminin receptor antibody targeting of liposomes with encapsulated doxorubicin to human breast cancer cells in vitro.
    Rahman A; Panneerselvam M; Guirguis R; Castronovo V; Sobel ME; Abraham K; Daddona PE; Liotta LA
    J Natl Cancer Inst; 1989 Dec; 81(23):1794-800. PubMed ID: 2531230
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chemotherapy and immunotherapy of bovine leukosis.
    Onuma M; Yasutomi Y; Yamamoto M
    Vet Immunol Immunopathol; 1989 Oct; 22(3):245-54. PubMed ID: 2560856
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Monoclonal antibody administration. Current clinical pharmacokinetic status and future trends.
    Begent RH; Pedley RB
    Clin Pharmacokinet; 1992 Aug; 23(2):85-9. PubMed ID: 1511531
    [No Abstract]   [Full Text] [Related]  

  • 55. Basic approach to application of liposomes for cancer chemotherapy.
    Hashimoto Y; Suzuki S
    Tohoku J Exp Med; 1992 Oct; 168(2):361-9. PubMed ID: 1306321
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug targeting with monoclonal antibodies. A review.
    Blakey DC
    Acta Oncol; 1992; 31(1):91-7. PubMed ID: 1637417
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The preparation and characteristics of immunoliposomes for targeting to tumour cells (A 431).
    Hudson MJ; Jones MN
    Biochem Soc Trans; 1991 Nov; 19(4):415S. PubMed ID: 1794540
    [No Abstract]   [Full Text] [Related]  

  • 58. Phototoxic liposomes coupled to an antibody that alone cannot modulate its cell-surface antigen kill selected target cells.
    Yemul S; Berger C; Katz M; Estabrook A; Edelson R; Bayley H
    Cancer Immunol Immunother; 1990; 30(6):317-22. PubMed ID: 2302722
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Targeting of magnetically responsive drug carriers to cancer].
    Morimoto Y; Natsume H
    Nihon Rinsho; 1989 Jun; 47(6):1432-6. PubMed ID: 2770004
    [No Abstract]   [Full Text] [Related]  

  • 60. Liposomes revisited.
    Lasic DD; Papahadjopoulos D
    Science; 1995 Mar; 267(5202):1275-6. PubMed ID: 7871422
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.